IMCR
Immunocore
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
IMCR Profile
Immunocore Holdings Plc
A commercial-stage biotechnology company that developing immunotherapies with T-cell receptors to treat cancer, infectious and autoimmune
Biological Technology
01/07/2021
02/05/2021
NASDAQ Stock Exchange
493
12-31
Depository Receipts (Ordinary Shares)
92 Park Drive, Milton Park, Abingdon, Oxfordshire , United Kingdom OX14 4RY
--
Immunocore Holdings plc was incorporated on January 7, 2021 under the laws of England and Wales. The company is a commercial-stage biotechnology company that creates and delivers transformative immunomodulatory drugs that fundamentally improve outcomes for patients with cancer, infectious diseases and autoimmune diseases. Leveraging the Company's proprietary, flexible, off-the-shelf ImmTAX platform, the Company is developing a deep pipeline across multiple therapeutic areas, including clinical-stage programs in oncology and infectious diseases, advanced preclinical programs in autoimmune diseases, and early stage preclinical programs across three therapeutic areas. In 2022, the Company received FDA, European Commission and health authorities approval for the lead product KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.